Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.

Diabetologia - 1 May 2024

Cardoso Pedro, Young Katie G, Nair Anand T N, Hopkins Rhian, McGovern Andrew P, Haider Eram, Karunaratne Piyumanga, Donnelly Louise, Mateen Bilal A, Sattar Naveed, Holman Rury R, Bowden Jack, Hattersley Andrew T, Pearson Ewan R, Jones Angus G, Shields Beverley M, McKinley Trevelyan J, Dennis John M

Abstract excerpt

AIMS/HYPOTHESIS: A precision medicine approach in type 2 diabetes could enhance targeting specific glucose-lowering therapies to individual patients most likely to benefit. We aimed to use the recently developed Bayesian causal forest (BCF) method to develop and validate an individualised treatment selection algorithm for two major type 2 diabetes drug classes, sodium-glucose cotransporter 2 inhibitors (SGLT2i)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bayes Theorem
Share to Diabetes Mellitus, Type 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Treatment and Management

Share to Genetic Associations and Epidemiology

Share to Glucagon-Like Peptide-1 Receptor

Share to Glucose

Share to Hypoglycemic Agents

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 38388753
DOI: 10.1007/s00125-024-06099-3
PMCID: PMC10955037

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.PMID 38388753Read ↗

Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetesSemantic proximity Read ↗

Derivation and validation of a type 2 diabetes treatment selection algorithm for SGLT2-inhibitor and DPP4-inhibitor therapies based on glucose-lowering efficacy: cohort study using trial and routine clinical dataSemantic proximity Read ↗

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A 2x2 Factorial Mendelian Randomization StudySemantic proximity Read ↗

Glucagon-like peptide-1 receptor agonist initiation and risk of clinically recorded Alzheimer's disease-type dementia in older adults with type 2 diabetes: a target trial emulation using causal machine learningSemantic proximity Read ↗

Safety and effectiveness of SGLT2-inhibitors in people with type 2 diabetes over 70: UK population-based study using an Instrumental Variable approachSemantic proximity Read ↗

Heterogeneity of Treatment Effects of Glucose-lowering Drug Classes for Type 2 Diabetes: LEGEND-T2DM Network Real-World EvidenceSemantic proximity Read ↗

Pharmacogenomics of GLP-1 Receptor Agonists: A genome wide analysis of observational data and large randomized controlled trialsSemantic proximity Read ↗

GLP1R Variants and Polygenic Risk Underlie Heterogeneous Response to GLP-1 Receptor Agonists in Type 2 DiabetesSemantic proximity Read ↗

Identifying type 1 and 2 diabetes in population level data: assessing the accuracy of published approachesSemantic proximity Read ↗

A Real-World Blueprint for Precision Diabetes Care: Integrating Pharmacogenomics into Clinical Decision-Making for A Chinese T2DM CohortSemantic proximity Read ↗

Leveraging Genetic Correlations to Prioritize Drug Groups for Repurposing in Type 2 DiabetesSemantic proximity Read ↗

CETP and SGLT2 inhibitor combination therapy improves glycemic controlSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.